Why Do Rare Disease Patients Spend an Average of Five Years Without a Diagnosis, and What Do Fragmented Records Have to Do With It?

People who have been diagnosed often go through a journey lasting more than five years before a confirmed diagnosis. Along the way, many receive at least one incorrect diagnosis and consult multiple specialists, each of whom holds only part of the medical record. This journey and the fragmentation it creates can slow diagnosis for patients and limit the research that could shorten the wait.

What Makes a Disease "Rare"?

Rare diseases affect far more collective individuals than their name suggests. In the United States, a disease that affects fewer than 200,000 people carries the designation "rare." There are between seven thousand and eight thousand identified rare diseases, and they collectively affect roughly 300 million people worldwide. Despite that collective scale, each individual disease touches a tiny slice of the population; and that rarity shapes everything about how patients are diagnosed, treated, and supported.

The economics of drug development for small patient populations differ substantially from mass-market medications. Treatment costs frequently reach six figures annually, and some therapies exceed one million dollars per patient per year. That cost reflects the reality of developing a treatment for a condition where a clinical trial may enroll dozens of patients rather than thousands.

‍

The Journey Before Anyone Has a Name for It

For most rare disease patients, the path to diagnosis is long and difficult. Patients wait an average of five to seven years for a confirmed diagnosis, during which time many receive at least one incorrect diagnosis and consult multiple specialists. Symptoms that could indicate dozens of conditions often lead clinicians down paths that don't converge on the right answer for years.

Once a diagnosis arrives, the challenges shift rather than resolve. Most rare diseases are chronic, progressive, and debilitating and need to be managed across a lifetime rather than with a single treatment course.Ongoing care typically involves multiple specialists across different organ systems. Coordinating those relationships, keeping records current, and ensuring each provider has the information the others have generated falls largely to the patient and their family or caregivers. The administrative burden of rare disease care is itself a form of labor that rarely gets acknowledged.

Social support fills in where the medical system falls short. Facebook groups, condition-specific online forums, and disease advocacy organizations have become primary sources of information, community, and practical guidance for rare disease patients. These networks carry knowledge the clinical literature may not yet contain, because patients often accumulate experience with their condition faster than research can formally document it.

‍

Where the Rare Disease Landscape Stands Now

The rare disease market is growing. Projections suggest the sector could reach approximately $500 billion in annual value by the early 2030s, driven by a pipeline of orphan drug approvals expected to continue at 20 to 25 or more per year. Investment is increasing, and patient populations that once had no treatment options are gaining them.

Artificial intelligence is also changing how rare diseases get diagnosed. Machine learning models trained on symptom patterns and phenotypic data can surface rare disease diagnoses that clinicians had not yet considered, expanding the practical reach of any individual physician's diagnostic knowledge. AI tools are being piloted in genomic interpretation, symptom clustering, and differential diagnosis, with promising early results in conditions that have historically taken years to identify.

Data infrastructure remains a persistent gap in the field. While oncology has had access to high quality real-world data for a decade, real-world data for rare disease populations is much more difficult to aggregate and curate due to the fragmented care patients receive. Data exists across hospital systems, specialty clinics, patient registries, and research databases, but it is fragmented, inconsistently structured, and difficult to aggregate. Researchers studying a rare condition may find that combining data from multiple sources requires more time and effort than the analysis itself. The volume of available data sounds meaningful in aggregate; in practice, each individual source is thin, and connecting them is hard.

‍

Why Real-World Data Infrastructure Matters

The rare disease patient's medical record is, for most conditions, scattered. No single system holds the complete picture, and the consequences of that fragmentation accumulate over time: In delayed diagnoses, in research studies built on incomplete populations, and in treatment decisions made without the full history.

Real-world data has the potential to bridge those gaps, but only when it connects fragments into something coherent rather than adding another silo to an already fragmented landscape. Registries that ingest data from multiple sources, standardize it against shared frameworks, and surface it back to researchers and clinicians in usable form transform a scattered record into a resource a research question can actually reach. Engaging patients throughout that process is crucial: patients must understand why their participation matters, who receives value from contributing, and trust the organization collecting their data stays enrolled. Longitudinal data requires longitudinal relationships.

The rare disease field has the potential for a significant decade of progress: an expanding drug pipeline, improving diagnostic tools, organized and sophisticated patient communities, and growing regulatory support. The connective tissue holding those ingredients together is data infrastructure capable of seeing a patient population that no single institution has ever fully seen at once.

‍

Novellia builds patient registries that connect fragmented records and engage rare disease populations over time. If you work in rare disease research, clinical care, or patient advocacy and want to learn more about how registry infrastructure supports your work.

‍

What Are the Most Common Questions About Rare Diseases?

• What is a rare disease? In the United States, a rare disease affects fewer than 200,000 people. Between seven thousand and eight thousand rare diseases have been identified, and together they affect roughly 300 million people worldwide.
• How long does it take to get a rare disease diagnosis? Patients wait an average of five to seven years for a confirmed diagnosis. Many receive at least one incorrect diagnosis and consult multiple specialists along the way.
• Why do rare disease treatments cost so much? Developers build these treatments for small patient populations, and a clinical trial may enroll dozens of patients where mass-market trials enroll thousands. Annual costs frequently reach six figures, and some therapies exceed one million dollars per patient per year.
• How does AI help diagnose rare diseases? Machine learning models trained on symptom patterns and phenotypic data can surface diagnoses that clinicians had not yet considered. Teams are piloting AI tools in genomic interpretation, symptom clustering, and differential diagnosis.
• Why is real-world data hard to use in rare disease research? Data sits across hospital systems, specialty clinics, patient registries, and research databases. It is inconsistently structured, and each individual source is thin, so combining sources can take more time and effort than the analysis itself.
• What is a rare disease patient registry? A registry ingests data from multiple sources, standardizes it against shared frameworks, and returns it to researchers and clinicians in usable form. It turns a scattered record into a resource a research question can reach.
• Why does patient engagement matter in rare disease registries? Patients need to understand why their participation matters and who receives value from their contribution. Trust keeps patients enrolled, and longitudinal data requires longitudinal relationships.

‍

References 

1. Burgun A, Khnaisser C, Dault R, Ethier JF. Exploring needs and priorities in digital health management for rare disease patients and their caregivers: A mixed-methods study. PLOS Digit Health. 2026 Sep 28;5(9):e0001240. doi: 10.1371/journal.pdig.0001240. PMID: 42804495; PMCID: PMC13618911.
2. Ho ML, Zitnik M, Azachi R, Basu S, Rajpurkar P, Sidlow R. Unifying the odyssey: artificial intelligence for rare disease diagnosis and therapy. Health Technol (Berl). 2026 Mar 10:10.1007/s12553-026-01057-y. doi: 10.1007/s12553-026-01057-y. Epub ahead of print. PMID: 41940139; PMCID: PMC13045663.
3. Mercer, E., Barder, T., Austraat-Churik, T., Torani, V., & Sullivan, M. (2026, February 12). Rare disease therapies: Four trends to watch. Blue Matter Consulting. https://bluematterconsulting.com/insights/blog/rare-disease-therapies-trends-2026/
4. Soriano-Martin P, Ruiz-González C, Alias-Castillo AJ, Roman P, Martinez-Ortigosa A, Bertini-Pérez D, Font Jímenez I. Lived Experiences of Patients With Rare Diseases and Healthcare System Barriers: A Phenomenological Study. J Nurs Manag. 2026;2026(1):e6754802. doi: 10.1155/jonm/6754802. PMID: 42374790; PMCID: PMC13315831.
5. U.S. Food and Drug Administration. (2026, September 28). Rare disease drug approvals. Center for Drug Evaluation and Research, Accelerating Rare Disease Cures (ARC) Program.https://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/rare-disease-drug-approvals

‍